95
Participants
Start Date
August 18, 2020
Primary Completion Date
March 16, 2022
Study Completion Date
March 16, 2022
GWP42003-P
oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
Placebo
oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
Clinical Trial Site, New York
Clinical Trial Site#1, Belgrade
Clinical Trial Site#2, Belgrade
Clinical Trial Site, Niš
Clinical Trial Site, Cedarhurst
Clinical Trial Site, Rochester
Clinical Trial Site#1, Kovin
Clinical Trial Site#2, Kovin
Clinical Trial Site, Oviedo
Clinical Trial Site, Lauderhill
Clinical Trial Site, Tampa
Clinical Trial Site, Largo
Clinical Trial Site#1, Kragujevac
Clinical Trial Site#2, Kragujevac
Clinical Trial Site#3, Kragujevac
Clinical Trial Site, Salamanca
Clinical Trial Site, Beachwood
Clinical Trial Site, Valladolid
Clinical Trial Site, Lincolnwood
Clinical Trial Site, St Louis
Clinical Trial Site, Shreveport
Clinical Trial Site, Bentonville
Clinical Trial Site, Richardson
Clinical Trial Site, Las Vegas
Clinical Trial Site, Lemon Grove
Clinical Trial Site, Garden Grove
Clinical Trial Site, Little Rock
Clinical Trial Site, Oakland
Clinical Trial Site, Pico Rivera
Clinical Trial Site, Berlin
Clinical Trial Site, Bełchatów
Clinical Trial Site, Gdansk
Clinical Trial Site, Kielce
Clinical Trial Site, Kobierzyce
Clinical Trial Site, Poznan
Clinical Trial Site, Torun
Clinical Trial Site, Wroclaw
Clinical Trial Site, Wroclaw
Clinical Trial Site, Barcelona
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY